Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Executive Summary
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)